Is GHK-Cu safe?
- Name
- GHK-Cu
- Also known as
- Copper peptide, Glycyl-L-histidyl-L-lysine copper
- Class
- Copper-binding tripeptide
- Verdict
- Unapproved Not approved; evidence thin or absent
- Human evidence
- Limited
- Updated
- October 2026
What is GHK-Cu?
GHK-Cu is a short peptide of three amino acids (glycine, histidine and lysine) bound to a copper ion. It occurs naturally in human blood plasma, and levels are reported to fall with age. It is an ingredient in many cosmetic serums and creams, and it is also sold online as an injectable for recovery and anti-aging. The two uses are very different in evidence and regulation.
What it is claimed to do
These are the uses GHK-Cu is promoted for. Listing a claim is not endorsing it — the next section is where each one meets the evidence.
- Improving the appearance of skin: fine lines, firmness and photodamage (topical)
- Wound healing and tissue repair
- Hair-growth support (topical and injectable claims)
- General anti-aging (injectable claims)
What the human evidence shows
For topical use, the human evidence consists of small, short studies of skin appearance, many with limited blinding or industry involvement, so benefits are plausible but modestly supported. For injectable GHK-Cu, the FDA reports limited data in humans to inform safety, and there are no large, well-controlled trials showing that injections deliver the anti-aging or healing benefits claimed online. Much of the broader excitement comes from laboratory and animal work. You can read the primary literature through the PubMed search linked below.
Known risks and side effects
- Topical products: skin irritation or allergic reaction is possible, as with any cosmetic ingredient.
- Injectable products: the FDA links the risk of immune reactions to aggregation and peptide-related impurities, and reports limited human safety data.
- Copper is an essential mineral, but its effect when delivered as an injection in high amounts has not been established for this use.
- Quality of injectable products sold as research chemicals is unregulated.
Legal status
Regulatory status as of October 2026. Approval, prescription status and compounding restrictions change without notice, and the two countries move independently. Check the regulator directly before relying on any of it.
United States
- Approved for human use
- No — not approved by the FDA for any human use
- Prescription only
- Not applicable or not yet determined
Topical GHK-Cu is sold as a cosmetic ingredient. Injectable GHK-Cu is not FDA approved. The FDA lists GHK-Cu for injectable routes among bulk drug substances nominated for compounding and then withdrawn, citing immunogenicity risk and limited human data. It was not among the six peptides the FDA advisory committee voted on in July 2026 or covered by HHS's October 2026 draft enforcement policy.
Canada
- Approved for human use
- No — not approved by Health Canada for any human use
- Prescription only
- Not applicable or not yet determined
Topical GHK-Cu products are sold as cosmetics. We found no authorization of injectable GHK-Cu as a drug in Canada; products sold online as research chemicals are not authorized for human use.
Who should avoid GHK-Cu
- You are considering injecting a product obtained outside a licensed pharmacy.
- You are pregnant or breastfeeding and thinking of anything beyond ordinary cosmetic use.
- You have a copper-metabolism condition such as Wilson disease; ask your doctor before using copper-containing products.
Frequently asked questions
Is GHK-Cu safe?
Used topically in skincare, it is generally treated like other cosmetic ingredients, with irritation possible. Injectable GHK-Cu has limited human safety data and is not approved, and the FDA flags immune-reaction and impurity concerns.
Does GHK-Cu work for anti-aging?
Small studies suggest some improvement in skin appearance with topical products, but the evidence is modest. Claims about injectable GHK-Cu go well beyond the human evidence.
Is GHK-Cu legal?
Topical products are sold lawfully as cosmetics. Injectable GHK-Cu is an unapproved drug in the US, and we found no authorization for it in Canada.
Sources
- FDAFDA: bulk drug substances that may present significant safety risks (GHK-Cu)
- PubMedPubMed: GHK-Cu research